Navigation Links
UCSF Enters Drug Discovery Agreement with Genentech
Date:2/18/2010

The University of California, San Francisco has signed a partnership agreement with Genentech, Inc., a wholly owned member of the Roche Group, to discover and develop drug candidates for neurodegenerative diseases.

(Vocus) February 18, 2010 -- The University of California, San Francisco has signed a partnership agreement with Genentech, Inc., a wholly owned member of the Roche Group, to discover and develop drug candidates for neurodegenerative diseases.

Through the agreement, Genentech will provide funding and its research acumen in neuroscience and will collaborate with UCSF to identify small molecules.

Genentech will support the work of several researchers at the UCSF Small Molecule Discovery Center (SMDC), which is administered by the UCSF School of Pharmacy and located in the California Institute for Quantitative Biosciences (QB3) on the UCSF Mission Bay campus. A research team at Genentech will work closely with UCSF to develop a drug candidate based on prior academic research conducted at the SMDC and discoveries at Genentech.

In addition to receiving financial support from Genentech for its research function, UCSF has the potential for further funding in excess of $13 million, if certain development and commercial milestones are met, plus royalties.

This is the first major collaboration the SMDC has formed with an industry partner, according to Jim Wells, PhD, who founded the center in 2005 and serves as its director. Wells and the center’s associate directors -- Adam Renslo, PhD, and Michelle Arkin, PhD -- will lead the project in collaboration with the Genentech team.

“What is transformative about this agreement from the University’s perspective is that it is a true collaboration between UCSF and Genentech scientists with the intent to generate drug candidates. This is different from a standard out-license or simple research collaboration,” said Wells, who is also chair of the Department of Pharmaceutical Chemistry in the UCSF School of Pharmacy and a faculty affiliate of QB3.

“Finding targeted compounds is a major obstacle in the drug discovery process, in part because most academic researchers don’t have access to this type of facility,” Wells said. “This collaboration shows how a center like the SMDC can help support the path from new biology into therapeutic products to help improve patients’ lives.”

This collaboration builds upon the existing master agreement between Genentech and UCSF, which allows the two to collaborate in a streamlined manner.

“We are very pleased to enter this agreement and are hopeful that together we can develop new treatments to help people with neurodegenerative diseases,” said Marc Tessier-Lavigne, PhD, executive vice president, research and chief scientific officer of Genentech. “To date we have entered into more than 15 research collaborations with UCSF, across several therapeutic areas. We believe that this latest agreement with SMDC enhances our relationship with the University and creates a new model for important industry-academic drug development partnerships.”

The partnership also coincides with the UCSF School of Pharmacy’s goal of shaping the future of pharmacy science by working in fresh, collaborative ways, according to Mary Anne Koda-Kimble, PharmD, dean of the UCSF School of Pharmacy.

“This is a tremendous new partnership and one that fits perfectly with one of the school’s major strategic goals,'' Koda-Kimble said. ''Our work with QB3 is a great example of how we are doing this. We believe the new UCSF partnership with Genentech takes this to a whole new level.”

The SMDC offers all UC biomedical researchers access to modern small-molecule discovery technologies, including high-throughput screening and follow-up medicinal chemistry. The center performs biochemical and cell-based assays using liquid handling robots and a screening library of more than 180,000 compounds. It also houses a group of medicinal chemistry researchers who optimize screening hits into drug leads. Over the past four years, the center has grown to 18 biologists and chemists, many with pharmaceutical experience.

The center is based on high-throughput screening, medicinal chemistry, and fragment-based screening, including a novel approach called “Tethering,” which Wells pioneered in his previous role as founder, president, and chief scientific officer at Sunesis Pharmaceuticals, Inc.

The center acts as a central research facility for scientists whose research would benefit from such technology. Its ultimate goal is to help pave the way for the discovery of new small molecules for research and potential therapeutics.

Small-molecule drugs -- which target a specific protein or enzyme that modulates a biochemical or cellular process and have the potential to alter disease states -- have traditionally been highly effective but are difficult to identify through standard, high-throughput screening.

QB3 is a cooperative effort among private industry and more than 200 scientists at UCSF, UC Berkeley and UC Santa Cruz. The institute harnesses the quantitative sciences of information technology, imaging and engineering to integrate and enhance scientific understanding of biological systems at all levels, enabling scientists to tackle problems that have been previously unapproachable. For more information, visit www.qb3.org.

The UCSF School of Pharmacy is the nation’s premier graduate-level school of pharmacy, the oldest pharmacy school in the western U.S., and a wellspring for discovery and innovation in the pharmaceutical sciences, education, and the pharmaceutical care of patients. For more information, visit http://pharmacy.ucsf.edu/.

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. For further information, please visit www.ucsf.edu.

###

Read the full story at http://www.prweb.com/releases/neurodegenerative_disease/drug_discovery/prweb3624334.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
2. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
3. Atlanta Falcons Physical Therapy Centers Set to Launch This Fall
4. Navitas Opens New Cancer Rehabilitation Center in Albuquerque in Conjunction With New Mexico Cancer Centers
5. Medicare Prescription Drug Benefit, Nonprofit Hospitals, Ambulatory Surgery Centers, Statistical Methods, and Pay-For-Performance Highlighted In the Latest INQUIRY Journal
6. Service-to-Sales Transformation at Contact Centers Hinges on Soft Skills
7. The First Incisionless Transoral Fundoplication for Treatment of Gastroesophageal Reflux is Performed in the U.S. at Ohio State University and Oregon Health & Science University Medical Centers
8. Community Health Centers Reveal Specific Ramifications of The Medicaid Citizenship and Identification Documentation Requirements
9. Commercial Insurers Reimbursement Rate to New Yorks Community Health Centers Jeopardizes Care
10. Pennsylvania Trauma Systems Foundation Accreditation Status for Trauma Centers
11. Vangent, Inc. Wins Spot on Centers for Medicare & Medicaid Services Enterprise System Development Contract
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UCSF Enters Drug Discovery Agreement with Genentech 
(Date:2/20/2017)... (PRWEB) , ... February 20, 2017 , ... Researchers at ... thyroid cancer, as well as a marker that may predict response to a particular ... many other types of cancer as well. The new findings were published in Proceedings ...
(Date:2/20/2017)... ... February 20, 2017 , ... Sensogram Technologies ... by for a visit this week at HIMSS 2017 Conference & Exhibition. The ... the globe. Sensogram will be featured in the conference’s Connected Health Experience section, ...
(Date:2/20/2017)... ... February 20, 2017 , ... Johns Hopkins All Children's ... building. A topping out ceremony on Friday marked the halfway point of construction and ... open in Fall 2018, will serve as a center for innovation aimed at finding ...
(Date:2/19/2017)... ... 19, 2017 , ... The Citadel’s new Swain Department of Nursing , ... Amelia Joseph, Ph.D. Joseph was engaged by the college as a consultant to help ... 2016. After a nation-wide search, she was selected to head the department as nurse ...
(Date:2/19/2017)... ... February 19, 2017 , ... Orbita, Inc., a ... with Healthwise ® at HIMSS 2017 to showcase a breakthrough ... health education, technology and services, will demonstrate a voice-powered knowedge assistant based on ...
Breaking Medicine News(10 mins):
(Date:2/19/2017)... SAN FRANCISCO and ORLANDO, Fla. ... (Nasdaq: NKTR ) today announced that positive ... NKTR-214, in patients with renal cell carcinoma (RCC) were ... immuno-stimulatory therapy designed to expand specific cancer-fighting T cells ... tumor micro-environment and increase expression of PD-1 on these ...
(Date:2/18/2017)... , Feb. 17, 2017 Research and Markets has ... report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America , ... period 2015 through 2022. Also, a six-year historic analysis is provided for ...
(Date:2/17/2017)... Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, Microwave, Radiofrequency, Ultrasound, Cardiovascular, Gynaecology, ... expected to grow at a CAGR of 9.4% from 2017-2022 and ... at a CAGR of 9.5% from 2017 to 2027. The market ... ... benefit you Read on to discover how you can exploit ...
Breaking Medicine Technology: